Inspire Medical Systems, Inc. (INSP)

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Inspire Medical Systems, Inc. - INSP

NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Inspire Medical Systems, Inc. (“Inspire” or the “Company”) (NYSE: INSP). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Inspire Medical Systems, Inc. - INSP

NEW YORK , Sept. 8, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Inspire Medical Systems, Inc. ("Inspire" or the "Company") (NYSE: INSP).

Inspire Medical Systems, Inc. (INSP) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Inspire Medical Systems, Inc. (NYSE:INSP ) Wells Fargo 20th Annual Healthcare Conference 2025 September 3, 2025 11:00 AM EDT Company Participants Carlton Weatherby - Chief Strategy and Growth Officer Ezgi Yagci - Vice President of Investor Relations Conference Call Participants Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Presentation Larry Biegelsen Senior Medical Device Equity Research Analyst All right. Good morning.

Why Is Inspire (INSP) Up 7.5% Since Last Earnings Report?

Inspire (INSP) reported earnings 30 days ago. What's next for the stock?

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Inspire Medical Systems, Inc. - INSP

NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Inspire Medical Systems, Inc. (“Inspire” or the “Company”) (NYSE: INSP).

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Inspire Medical Systems, Inc. - INSP

NEW YORK , Aug. 27, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Inspire Medical Systems, Inc. ("Inspire" or the "Company") (NYSE: INSP). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Inspire Medical Systems, Inc. - INSP

NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Inspire Medical Systems, Inc. (“Inspire” or the “Company”) (NYSE: INSP). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

Is the Options Market Predicting a Spike in Inspire Medical Systems Stock?

Investors need to pay close attention to INSP stock based on the movements in the options market lately.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Inspire Medical Systems, Inc. - INSP

NEW YORK, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Inspire Medical Systems, Inc. (“Inspire” or the “Company”) (NYSE: INSP). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

INSP Investors Have Opportunity to Join Inspire Medical Systems, Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES , Aug. 12, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Inspire Medical Systems, Inc. ("Inspire" or "the Company") (NYSE: INSP) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Inspire Medical Systems, Inc. Board Authorizes Share Repurchase Program

MINNEAPOLIS, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire, or the company), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today announced that its Board of Directors has authorized the repurchase of up to $200 million of the company's outstanding shares of common stock.

Baron Discovery Fund Q2 2025: Winners And Setbacks Shaping The Portfolio

Kratos Defense, Montrose Environmental, and Karman Holdings drove strong quarterly performance, benefiting from secular tailwinds and robust demand in defense and environmental sectors. We see Kratos and Karman as well positioned for multi-year growth, leveraging investments in hypersonics, missile defense, and space technologies amid rising defense budgets. Montrose Environmental rebounded as regulatory fears eased, organic growth accelerated, and debt reduction improved transparency, supporting our continued conviction in its long-term value.

Inspire Medical Stock Strays Off Course Amid Structural Setback

Inspire Medical Systems, Inc. Investors: Company Investigated by the Portnoy Law Firm

Investors can contact the law firm at no cost to learn more about recovering their losses

INVESTOR ALERT: Investigation of Inspire Medical Systems, Inc. (INSP) Announced by Holzer & Holzer, LLC

ATLANTA, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Inspire Medical Systems, Inc. (“Inspire Medical” or the “Company”) (NYSE: INSP) complied with federal securities laws. On August 4, 2025, Inspire Medical announced second quarter 2025 results and updated its 2025 outlook, stating that “the U.S. commercial launch is progressing slower than expected, and the timeline to complete the full transition to Inspire V has been pushed forward, which will impact financial results for the year.” Following this news, the price of the Company's stock dropped.

INSP Stock Plunges Despite Q2 Earnings Beat, Gross Margin Contracts

Inspire Medical tops second-quarter 2025 earnings estimates and posts solid revenue growth, but trims 2025 guidance amid margin pressure.

Inspire Medical Systems Crashes 32% As Eli Lilly's GLP-1 Weighs On Guidance

Inspire Medical Systems crashed Tuesday after the maker of implantable sleep apnea devices called out GLP-1 drugs for weighing on sales.

Inspire Medical Systems (INSP) Expected to Beat Earnings Estimates: Should You Buy?

Inspire (INSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Is the Options Market Predicting a Spike in Inspire Medical Systems Stock?

Investors need to pay close attention to INSP stock based on the movements in the options market lately.

Inspire Medical Systems, Inc. to Present at the Truist Securities MedTech Conference

MINNEAPOLIS, June 03, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the Truist Securities MedTech Conference on Tuesday, June 17, 2025. Inspire is scheduled to present at 11:20 a.m.

Dr. Jose Jacob Scholarship for Future Doctors Opens Nationwide: A Timely Opportunity to Inspire Medical Students to Address Real-World Healthcare Challenges

OCALA, Fla., May 07, 2025 (GLOBE NEWSWIRE) -- The Dr. Jose Jacob Scholarship for Future Doctors is now officially open for applications, offering a one-time award of $1,000 to undergraduate students across the United States who are committed to pursuing a career in medicine.

All You Need to Know About Inspire (INSP) Rating Upgrade to Buy

Inspire (INSP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Wall Street Analysts Predict a 39.04% Upside in Inspire (INSP): Here's What You Should Know

The consensus price target hints at a 39% upside potential for Inspire (INSP). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

INSP Stock Gains Following Q1 Earnings Beat, Gross Margin Contracts

Inspire Medical's first-quarter 2025 performance reflects increased market penetration in existing centers and expansion into new territories and centers, along with strong domestic results.

Inspire Medical Systems, Inc. Announces the Addition of Paul T. Hoff, M.D.

MINNEAPOLIS, April 21, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today announced that two leading physicians in the field of sleep medicine and sleep surgery, Paul T. Hoff, M.D., M.S., an otolaryngologist, and Ruchir P. Patel, M.D., F.A.C.P., a sleep medicine specialist, will join Inspire in Vice President, Senior Medical Director roles, effective April 21 and June 2 respectively.

Here's Why Inspire Medical Systems (INSP) is a Strong Momentum Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

SHAREHOLDER ALERT: Kaskela Law LLC Announces Shareholder Investigation of Inspire Medical Systems, Inc. (NYSE: INSP) and Encourages Long-Term Inspire Investors to Contact the Firm

PHILADELPHIA, Feb. 17, 2025 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire Medical”) on behalf of the company's long-term shareholders.

INSP Stock Declines Despite Q4 Earnings Beat, Gross Margin Contracts

Inspire Medical's both geographic segments witness strong revenue growth on the back of solid product demand in the fourth quarter.